View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
December 21, 2021updated 11 Jul 2022 2:14pm

Everest and Providence’s Covid-19 vaccine included in WHO STV trial

The global, randomised STV clinical trial is assessing the efficacy and safety of potential Covid-19 vaccine candidates.

Everest Medicines and Providence Therapeutics have reported that their Covid-19 vaccine, PTX-COVID19-B, obtained approval to be part of the World Health Organization (WHO) Solidarity Trial Vaccines (STV) programme.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The inclusion comes after a recommendation from an independent advisory group.

A messenger ribonucleic acid (mRNA) vaccine, PTX-COVID19-B encodes the SARS-CoV-2 S protein encapsulated in a lipid nanoparticle.

The global, randomised STV clinical trial is assessing the efficacy and safety of potential Covid-19 vaccine candidates.

Based on pre-defined eligibility requirements, an independent vaccine prioritisation advisory group chooses the vaccines.

The criteria features a vaccine’s safety, its potential for efficacy, stability, ease of manufacturing for global supply and administration.

Sponsored by and funded by the WHO, the trials are currently enrolling subjects in selected study centres in the Philippines, Mali and Colombia.

The panel has so far reviewed the data from nearly 20 vaccines and included two vaccines of Medigen and Inovio, respectively, in the trial.

Individuals of the age 16 years and above residing in regions with greater Covid-19 incidence rates but were not infected or have not been inoculated form part of the trial.

All subjects in the trial will be followed up weekly for a minimum of one year on receiving the vaccines.

Everest Medicines CEO Kerry Blanchard said: “The STV trial complements the joint efforts of Everest and Providence in generating a robust safety and immunogenicity data set design.

“We hope this can help accelerate approval with regulatory bodies around the world.”

According to interim results from the Phase I trial of PTX-COVID19-B, the vaccine was found to offer robust virus neutralisation ability and induced antibodies levels in line with already approved Covid-19 mRNA shots.

Furthermore, treatment with PTX-COVID19-B was found to be safe and well-tolerated in the trial.

In September this year, Everest and Providence entered a definitive agreement to licence rights to the latter’s mRNA Covid-19 shots in some emerging markets in Asia.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena